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Abstract of Diss ertation
Th~ pres~nce of contaminants in parenteral sol~tions is
a constant nemesis against whic h pharmaceutical manufacturers,
as well as medical, pharmacy , and nursing practitioners mus t
vigilantly struggle to prov i de quality healt h care. At each
level in the parenteral drug delivery syst em, contamination
is possibl~ bc(ore the patient actually receives the infusion.
The imple~entation of better practices and procedures conti n ues
in the que s t of conta minan t-free parenterals. ~ e vertheless , the
literature is replete with articles documenting contamination of
parenteral ~edication .
foreign body parti culate matter has been found sequestered
in the lungs of patients who have received intravenous therapy.
The entrap~ent of forei~n bodies can occur in other body organs
besides the lun gs. The hazardous effects of this partic ~ late
matter has be en the subject of much concern. Other forms of
parenteral contaminants have been reported in the liter~ture.
These include both bacterial and fu"gal contaminants.
Contaminant detection in parenteral solutions has been
r.ccompli511ed by several methods . The s e have included: visua l
inspection , nep he lometric methods , methods of me~ brane
filtrati on with suhsequent microscopic examination, and methods
emplbyin~ various electronic adaptatibns .
No references have been pub lished describing vi ral
contamination of pnrenterals or r.1e t hods for viral det 2ction
in parenteral sol~tiuns . Yet, viral cont aminants infused directly
into the blood of a p a tient May be of grave clinical sig n ifica n ce .
Thu s, the objective of thi5 project was to develop a met~oj for
detecting the presence of vir~sus in small and bulk pare nt. cr<Jl
solutions.
Both s mall and larg e volumes of Sodium Chl oride Inj~ction
U.S . P. and S percent Dextrose Injection U. S .P . were i n oculated
~ith 100 I.U . or 1 I. U. of Tcbaccq ~1q?aic Virus (TMV) per ml
of solution . The contents of these parenterals were conce n trated
to a retentate vo!une using molecular filtra~ion . The retentate
volume wa s examined for viral content using transmiss i on electron
microscopy with negative staining techni~ues .
Effic acy was determined by comparison of the result s of
the contaminated controls wit h the contaminated te st groups .
Statistically significa"t differences we re observed between
the co"trol yroups, wnich were not ~ubjected to t he test met h od ,
and the t est uroups for bot h s mall and large volume ' parenteral
solutions .
Efficiency, which denotes the viral conta~ination l P. vel
at which viruses are detectable, wa s determined by comp~ring the
control groups of uncontaminated p a rentera l so l utio n s wit h
conta~lnated test gr~up~ of the same solutions . Both gruu p s
were subjected to the •est r.1ethodology . The control and the test
groups showed stat i ~tic a lly significant differences 3t t h e 100
and the 1 I. li. TrW contaninntion levels .
Th e results s h owed thnt the defined ~etnod of viral detection
i s ef ficacious and efficient at t h e t ested TMV contamin<Jtio n
level s . This method could probably be app li ed to the detection
of other viral contaminants of p a renteral solutions as well as to
bi o l ogica l viral anal y s ~ s method s .
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INTRODUCTION
The presence of contaminants in parenteral solutions is
a constant nemesis against which pharmaceutical manufacturers,
as well as medical, pharmacy, and nursing practi.cioners must
vigilantly struggle to provide quality health care.

At each

level in the parenteral drug delivery system, contamination
is possible before the patient actually receives the infusion therapy.

Through contemporary and future science and

technology, the implementation of better practices and procedures c:ontinues in the quest of contaminar1t-free parenterals.

Nonetheless, the literature is replete with articles

documenting contamination of parenteral medication.
The objective of this research project is to supplement
the quality control procedures for parenteral infusions with
a method capable of detecting viral contaminants in small
and large volume parenterals.

1

LI'fERATURE
Contaminants in Parenterals
ln 1949, Von Glahn and Hall ( 8) reported pulmonary em-boli of cotton fibers which resulted from intravenous injection of fluids containing cotton fibers.

At autopsy char-

acteristic. mononuclear infiltrates and multinucleated giant
cells were found at the intimal sites of the foreign body
lodgement.

These incidental findings were corroborated by

Konwaler's (9) report of pulmonary foreign body granuloma
in autopsi.ed cases hav.i.ng received intravE>nous therapy.
Subsequent artic.les appeared in the literature describing pulmonery

arteri~l

response to foreign bodies associated

with intravenous therapy (13,14).

Confirmatory experimental

studies using animals were also conducted (27,28).
As shown by Lie bow et al.

( 62) and Hales ( 61) arterio-

venous shunts in the. lung exist.

When these are present,

particulate contaminants of intravenous fluids may be
delivered to the general circulation and then be sequestered
in other body organs besides the lungs (26).
The impelling study of large volume parenteral contaminants originated in 1963 with the work of Garvan and Gunner (1).

These authors in their original article and sub-

sequent articles (2,3) described:

2

contamination levels of

l'

3

intravenous fluids, the nature and origin of the contaminants,
methods of particulate detection, the harmful effects of
particulate contaminated intravenous fluids both in animal
exper·imen ts

and patients, and compendial recommendations

for particulate detection, limits, and parenteral fluid
manufacturing.
Resulting from the interest generated by the works of
Garvan and Gunner, in July of l966·the Federal Food and
Drug Administration convened a Scientific Symposium on Large
Volume Parenteral Solutions (64).
symposium were to explore:

The bas:Lc purposes of the

the problems of parenteral solu-

tions, the health significance of particulate matter, and
the methods of minimiz:Lng intravenous flu:Ld hea.lth hazards.
At this symposium, the find:Lngs of vartous authors (l-·3,

10,13,14,27,28) were presented as evidence of l1azardous
effects associated with parenteral flutds.

Jonas (12)

described the potentially hazardous effects of introducing
particulate matter into the vascular system.

He stated that

the effects of the injected particulate matter depend on
three main factors:

1.

the size, shape, and chemical characteristics
of the particle,

2.

the site of occlm;ion a.11d degree of interruption
of blood supply, and

3.

the host response to the particle.

Included in the host response is the antigenic potential of
the particulate matter.

Lockhart (6) also addressed the

4

medical significance of particulate matter including inorganic particles, bacteria, and molds.

Gross and Carter (5)

described the pathogenic hazard of particulates in intravenous solutions causing pulmonary granulomatous inflammation.
They stated that the medical significance of the particulate
matter "rests essentially in a consideration of the state of
patients receiving large amounts of parenteral :fluids" and
that recumbent states and concomitant therapy especially with
large doses of corticosteroids are factors which influence
the pathogenicity of contaminated infusions.

Gross (7) in

a subsequent article described the possibility of pulmonary
arteriovenous shunts enabling particulate matter to obstruct
systemic circulation causing diminished blood supply to
vital organs.
Endicott et al.

(10) in the symposium's proceedings

related the significance, source, measurement, and elimination of particulate matter at the manufacturing level.
Yakowitz (11) described the problems associated with the
manufacture, storage, and use of large volume parenterals.
This symposium further stimulated interest in contaminants of large volume parenterals.

Turco, Davis, and

Sivelly (4) have quantitatively studied particulate matter
in large volume parenterals with and without additives using
a membrane fiJ.tratl.on technique.

They found that both addi-

tives and administration sets increased the number of par'

~

'

ticulates in intravenous solutions.

These authors further
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described the work of past investigators and related the
use of a final filter set for removing particulate matter.
Turco and Davis (15) presented a thorough review of
the literature on the clinical significance of particulate
matter.

Turco (33) has also described the hazards associ-

ated with parenteral therapy including microbial, pyrogenic,
and other forms of

particula~ e

contamination in parenteral

therapy.
The presence· of particulate matter has been reported in
commercial antibiotic injectables (23,24,29,30).
~t

Rebagay

al. (23) have proposed that the residues in antibiotic

preparations might react with tissue
contribut e to phlebitis.

~roteins

and cause or

Stewart (73) found traces of

macromolecul a r proteins of p ep tide complexes in natural
cephalosporins and penicillins which possessed allergenic
potential .

Thus, this type of particulate contaminant may

elici.t host immune response.
The cli.nical significance of particulate matter wa.s also
related in the Canadian Journal of Hospital Pharmacy (59).
Duma has rece ntly described the hazards of intravenous
therapy in the New England Journal of Medicine (22) and has
previously reported on particulate matter in the Annals of
Internal

M e d.:i. cin~

( 65) .

It is evident from the widespre ad

literature reports th a t contaminated parenterals are now of
unquestioned clinical concern.
Past works have describe d the possibility of microbial
and fungal contamination of parenterals (6,33) .

Numerous
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reports now document the possibility of bact e rial as well
as mycelial contamination and some have proposed recommendations as to surveillance of contaminated large volume
parente rals (19,20,21,35,36,38,39,51-55,58,60).
(60) cite case s of nosocomial
fluids and volume-control sets.

Duma et al.

septice mia from intravenous
Guynn et al. ( 35) found that

5 percent Dextrose Injection U.S.P. was the most hostile to
bacterial growth, whereas Sodium· Chloride Inj ect i on U.S.P.,
Lactated Ringer's Injection U.S.P., and 5 p e rcen t dextrose
in Lactate d Ringer's Injection we r e more conduc i ve to bacterial growth.

They found that gram-negative bacilli pre-

dominat e over gram-positive cocci. as fhe study of Duma et al.
(60) ha d a l s o indicated . . In the work of Por etz et al . (20)
most species of orga nisms isolated were commonly considered
lacking virul ence.

Yet, these same organisms may be patho-

genic in the debilitated , · hospitalize d patient.

Furthermore,

the elabor a tion of endotoxins by gram-negative bacilli
presents anothe r distin c t threat to th e patient from contaminated par e nt eral fluid s .

Wilkin son et al. (52) as well as

Curry and Quie (63) have shown the preponderance and prolifera tion of
solutions.

Can.~ida

al_bicans in pare nt e ral hyperalimentat ion

Deeb and Natsios (58) stated that contamination

of ''in us e " hypera.lime nta tion fluids by Candida species
occurs to an extent greater than 25 pe rcent.
In 1971, the clinica l significance of contaminated
large volume pare nte ral s was sadly r ealized.

Ove r 50 patients
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died as a result of infectioGs which they received from contaminated screw-cap infusions (37,50).

Resulting from this

tragedy, the United States Pharmacopeial Convention, funded
by the Feders_l Food and Drug Administration, organized the
Natl.onal Coordl.nating Comml.ttee on Large Volume Parenterals.
Barker ( 45 ), project dl.rector and chairman of the Committee,
has stated the Committee's purpose is to study the problems
associated wl.th large volume parenterals and coordinate
efforts of the member organizations in deall.ng wj.th these
problems.

Activity coordination, guidelines for problem

identification, recommendations, and increased awareness of
usage standards have resulted from the committee's endeavors
(31,37,41,44,45,50).
Included in a recent report of the National Coordinating
Committee on Large Volume Parenterals ( 4·1), it is recommended
that an inline particulate matter retentive final filter be
serl.ously eonsidered as a requirement for the administration
of large volume parenterals.

Thl.s recommendatl.on is based

upon numerous studies and their conclusions as to the overall
advantages of inline final filtratl.on (16,17,32,34,38-40,42,
55,66,110,123).

Some of the advantages arising from the use

of inline filtration ·as reported in the above studies
include:
1.

the effective removal of particulate matter
and resultant reduction of patient risk from
these contaminants,

2.

the decrease in microbial and pyrogenic contamination, and

8

3.

the decrease in the incidence of phl.ebitis.

Some of the disadvantages of inline filters are:
1.

reduced infusion flow rates especially with
the 0.22 micrometer (pm) filters,

2.

air entrapment in the filters stopping flow,

3.

non-bacterial retentioP capabilities of filters
used other than the 0.22 ~m filters (38), and

4.

the bothersome yet effective clogging of inline
filters with particulate matter .

These inherent disadvantages can be overcome by the use of
an air-venting, ·0.22

~m

inline filter with a large filtration

surface as reported by Rapp et a l. (42).
Contaminant Detect ion in Parent e rals
The det ect ion of particulate matt er
by several

me~ hods

~ as

b ee n accomplished

which are either nondestr uctive or destru c-

tive in n at ure (l-3,10,18,23,24, 29 ,30,43, 46 ,47,56,57,67).
Visual inspection unde r diffuse li ght has been used by
manufacturers (56,57) and in hospital pharmacy admixture
prog rams .

This nondes tru c tive met hod i s subj ect i ve , qualita-

tive not quantitative, and restrict e d to visualization of
particles greater than 50

~m

(56,57).

Bl a nchard et al.

(43)

fohnd thi s met hod inadeq uat e for mo nitorin g particulate
matt er in large volume pare nter a ls.
Nephelometric met hods u se

th~

Tyndall effect of visual

examination by the light scattering potential of particulates
in a bea m of light.
the

si~e

Particulate detection is dep e nde nt on

of the contaminant and the angle of scatter.
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Particles over one

~m

can be detected (56,57).

This nonde-

structive method provides qualitative comparison solution to
solution.

The method cannot distinguish types of particulate

matte:o:- and is not quantitative..

Garvan and Gunner

(l-3) and

others (67) have described its use.
Membrane filtration and subsequent microscopic examination is a destructive technique which has been used by
numerous investigators (1·-3,29,30,43,57).

This method pro-

vides a permanent record of particulate contamination and
can provide both qualitative and quantitative comparisons.
The method can be tedious and particles with refractive
indices similar to the filter can go ~ndetected.
light microscope particles of 0.2

~m

With the

size can be resolved (68).

This method has been adopted by the United States Pharma-·
copeia for particulate matter determination in large volume
injections for single-dose infusion (72).
The Coulter Countera has been used for the indirect
determination of particulate matter in parenteral infusions
(56,69,110).

This method is classed as a destructive tech-

nique for particulate detection.

It is a rapid, nonvisual

method using the principle of changes in electrical resistance caused by particulate matter in an electrically conductive solution.

Vessey and Kendall (56) recorded parti-

cles as small as 2.0

~m,

yet it is possible to detect

aCoulter Electronics, Hialeah, FL.

10

particles less than this size (10).
be directly

us~d

The Coulter Counter can

for electrolyte solutions only.

The Royco Liquid Countera is another instrument which
has been successfully applied to particulate determination in
injectable solutions (10,57,70).
manufacturing level (70).

It is

bei~g

used at the

As a batch · sampler this instrument

is categorized as providing a destructive me thod of indirect
determination uf particulates.

The principle of operation

is that of incident light scattering by contaminant particles
in a flowing stream of the solution.
nephelomet ric methods , but the

Thus, it is similar to

~ecrease

in li g ht r esulting

from a particJ.e's presence is actually measured by a light
sensing cell and amplified to produce a characteristic
pulse h eight (7Q).

It provides a rapid means .of particle

detection for both e l ectro ly te and non-el ect rolyt e s olutions (10,57).
as two

~m

It is capable of detecting particles as small

(70).

The Millipore TT MC P art icle Measurement Computer
Systemb is an electronically a utomat ed adaptation of the
membrane filtration and microscopic examination technique
(57 ~71).

The parenteral solution is fi ltered through a

me mbrane filter.

Th e filter with the collected particulate

matt e r is then examined by a microscope connected to a

a

bRoyco Instrumen ts, Menlo Park, CA
Millipore Corporation, Bedford, MA
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television camera.

The ima ge of the parti cu late i s processed

by a computer JTIOdule a nd displayed on a television monitor
(71) .

As Lim et al.

(57) have reported, this system "was

more prec i se in detection and sizing of particl es and more
rapid in counting of particles than th e micro scop ic manu a l
examination method."

The sy stem is capable of measuring

entire fields of particle s or selective indi v idual particles,
counting entire fi e lds , computing total area and ave rage are a
of particulate s , computing partiele size distribution s and
other paramete rs (71).
system i s 0.2

~m,

The resolution limit o f the TT MC

the limit of the optical microscope . (68,

71).
Anoth er i n s trument for th e analysis of particu l ate
t er in large volume parent erals i s the Pro'totr~on. a
a nd Graf (4 6 ) a nd Blanchard et al.

mat~

D:caftz

(43) h ave r epo rt ed o n

this instrument, whi c h u ses a l ase r -light scatteri n g princj_ple.

Sizj_ng and counting of particulates are made on the

parenteral conten ts in their cont ai n er a nd t h us the met h od
i s con sidered to b e n on d estr u ctive.

Both s tu dies (43,46)

r eporte d the inhere nt advantages and disadvantages of th e
Prototron and state d that it s u se should be f ur ther in vestigated.

As repo rt ed by Draftz a nd Graf (46), pa r ticles

g r eate r than o n e vm were recordable.
In a recent report La nt z et al.

(47) have described

a Th e Nu c l eopo r e Corpo r at ion, Pleasa nton, CA

12

the use of the HIAC Particle Countera for monitoring particulate matter in parenteral solutions.

This instrument

is a device using electronic stream scanning of particulates
in the solution and operates on the principle of light
blockage.

It is capable of rapid and accurate counting of

su.bvisual particles.

The work of Lantz et al. described

the advantages and disadvantages of this instrument.
Studies employing a membrane filtration technique
followed by scanning electron microscopy have recently been
presented in the literature demonstrating the value of this
method for the examination of.the topographical configuration
of particulate matter (18, 23,24, 109). · Levinson

e~

al.

(18)

used this method for "she comparison of infusion particu1 ates
found in gla<os and plastic containers.

Rebagay

~ a~.

(23,

24) used thi.s technique to observe residues in antibiotic
preparations.

Winding and Helma (109) have recently reported

the use of scanning electron microscopy and X--ray analysis
of particles exceeding 0.2

~m.

The X-ray analyzer coupled

to the microscope could not chemically identify biological
materials and other organic materials but could identify
elements 9 through 93 in the periodic table.
Viral Contamination of Parenterals
Various types of contaminants have been found in parenteral flulds and many methods have been used in their

~Ugh Accuracy Products, Clairmont, CA
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detection .

The articles published to date on large volume

parenterals have reported contaminants with particle size
above 0.2

~m .

The presence of particulates less than 0.2

has not yet been described for parenteral fluids .

~m

Thus,

the nature of these contaminants or their clinical significance cannot be assessed.
A suspected contaminant of large volume parenterals in
this submicron size range might be the virus.

Viruses are

reported to range from approximately 18 nanometers (nm), as
exemplified by the

PicornR..~_iruses,

as observed i.n the

~_oxv:~_ru.scs.

(98) .

the virus has and is still being

to about. 300 nm in size,
The significance of

reco~nized

in both clinical

medicine a nd epide miology.
If viral contaminant s exist in pare nt eral f luids, a
grave at,ci imp8nding danger exists for the patie n t r e ceiving
this "therapy."

A patient undergoing parenteral therapy

undoubt e dly receiv es it to facilitat e correction of some
pathological state .

Such an ill person may b e immunolo g ically

deficient at the t ime of· therapy.

As Gross and Carter ( 5)

have stated, recumbent positions and concomitant therapy
especially with large do s es of corticosteroids are factors
which influe nc e the pathogenicity of contaminated infus ions .
With the present medical trends in transplants and corres p o nd-ing use of immunosuppressants, viral contaminants infus e d
directly into the blood stre am of these patients ma y b e
clinically significant.

In those patients who are immuno-
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logically compe t ent, a parenterally infused virus can cause
disease (48).

Furthermore, slow, inapparent and r ecurr ent

viruses can persist in th e ir host without - the clini ca l signs
· of disease , yet cause chronic degenerative ma ladies clinically expresse d at future times (49).

Thus, any huma n virus

can be c U .nically signi f icant when administered p a r e nte rally
in an appropriate human hos t.

Only s p eculat i on is pos sibl e

about the health significance. o f par e nterall y infused nonhuman viruses .
The hypothesis that viruses may ccntamin a t e large
volume pare nt e rals receives support from the Ame ri can Public
Health As soc i at i on's concern r egardin g th e potential healt h
hazards of waterborn e viruse s .

Thi s Association's Inte r-

national Confe rence on Viru ses in Wate r was .he ld in Me xico
City in 1.974 (99,111).

Several recomme ndatio ns for e nviron-

mental health safety, r esearch, and de t ect i o n me thods
result ed from this conference (100,111) .

Articl es have

appeare d in the lite ratur e r egardin g the presence a nd significance of viruses in ·water supplies (101-106).

At

present, neithe r parenteral ma nufacture rs nor the Fe deral
Food and Drug Administration's Pare nt e ral Quality Control
Laboratori es routin e ly mo nitor
viruses (11 2 ) .

parente~al

contamination by

Personnel at a Fe de r a l Food and Drug Admin-

istration's Quality Control Labo ratory have expresse d th ei r
be lief that viruses could contaminate parenterals espec i a lly
where aseptic filling, final sterilization by filtr a ti on, or
parenteral admixture are p e rforme d (112).

1.5

Viral Contaminant De tection in Parenterals
The

initi~l

problem in the development of a met hod for

the de termination of virus contamination of parenterals is
that of concentration or extraction of the virus from these
solutions by an efficient me ans.
Chromatographic and me mbran e separation methods (92),
molecular sieving methods (93), electrophoretic methods (94),
ultracentrifugal methods (86-89), and filtration met hods (90,
91,107,108) have been used successfully in virus concentration.

Because of the quantity and the nature of the solu-

tions studie d, the filtration me thod is most amenable to
efficient concentration.
The specific filtration procedure which affords virus
concentration is molecular filtratj .on.

Molecular filtration

has be e n d esc. ribed as a "technique for separating dissolved
molecules on the basis of size by passing a solution through
an infinit esimally fine filter.

This molecular filter is

a tough, thin, sel ectively permeable membrane whicp retains
most macromolecul es above a certain size, while allowing
most smaller molecules, including solvent to pass into th e
filtrate" ( 108).

Molecular filters are ava.i lable with dif -·

ferent retention abilities which are characterized by their
nominal molecular weight limit.
weigh~s

Molecules with molecul a r

above this limit may be retained in a retentat e

volume, howe ver the size and shape of the molecul e also
influe nce retention phenomenon.

This nominal molecular

weight limit serves as a guide to filter selection.
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After filtration the retentate volume, usually less
than three milliliters (ml), contains the concentrated virus.
If it is necessary, the virus may be. further concentrated
by ultracentrifugation (107) or by further molecular filtration to even smaller retentate volumes (108).

.,'

Once virus concentration has been accomplished, electron
microscopic examination of this concentrate using negative
staining techniques allows visual detection of virus contaminants.

Through initial electron microscopic examination,

viruses can be classified into three general structural
configuraU.ons:

rod shaped, spher·ical, or tadpole shaped ( 98).

As shown by Horne and Wildy ( 82,84), virion synnnetry, especially caps1.d symmetry, is a useful criterion for virus
classification.

Negative staining methods for transmission

electron microscopy have provided valuable information in
the revelation and study of virus particles (74-85,96,97).
The "drop method" as deseribed by llaschemeyer and Myers (74)
is the most amenable technique for the embedding of the
specimen sample in the negative stain where viral concentrations may be low.

OBJEC'I'IVES
The primary objective of this project will be to develop an accepted research method for determining the presence
of viruses in small volume as well as bulk parenterals.
'!'he following methods and procedures used to attain
the objective of this endeavor will include:
l.

defined volumes of the parenterals will be
inoculated with specific quantities of Tobacco
Mosaic Virus var. vulgaris Ul, used as the
rnodelviral contaminan:r;-to test the efficacy
and efficiency of the detection method;

2.

the contents of the selected parenterals will
be concentrated to an appropriate retentate
volume using molecular filtration through a
filter of suitable nominal molecular ·wej_ght
limit, capable of retaining viruses;

3.

this retentate volume will be examined for
viral content using transmission electron
microscopy with negative staining techniques;

4.

defined volumes of Sodium Chloride Injection
U.S.P. and 5 percent Dextrose Injection U.S.P.
will be the parenteral infusions examined.
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EXPERIMENTAL
Definitions
In this research endeavor, a method was developed to
detect viral conta_minants in parenteral solutions.
method was analyzed for its efficacy and efficiency.

This
The

term "efficacy," as used in this project designated the
capability of viral detection by the method.

'l'he term "effi-

ciency" denoted the viral contamination level at which viruses
were detectable.
The Model Virus
The virus chosen for use as the inoculant· for contaminating the parenteral solutions was

Tobacc~?. Mosai~ V~rus

(TMV).

This RNA virus is a plant pathogen possessing well defined
rod shaped morphology and helical symmetry with respect to its
nucleic acid core.

The virus is approximately 300 nm in

length and 17 nm in diameter (82).

Most viruses studied to

date have sizes within this range (98).

Because TMV has

characteristic geometry and virion dimensions representative
of the major viral groups, this virus was used a_s the model
virus for this study.
Tobacco Mosaic Virus is a chemically stable virus and
shows an inactivation rate independent of pH in the range of

18
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4.0 to 8.5 (113).

A pure culture of the virus is stable in

dilution in Sterile Water for Injection U.S.P. for about a
year (114).

These factors were advantageous for viral sta-

bility considerations in the parenteral solutions examined.
Fraenkel-Conrat (115) described a relationship between
weight, viral particles, and plant lesions for TMV.

One

plant lesion is produced in Nicotiana tobaccum var. Xanthi
for approximately every 0.1 n~.nogram (ng) or 10 6 virus particles.

Thus, one infectious unit (I.U.) corresponds to

approximately 10 6 virus particles for TMV (116).
In this experimentation, viral dilutions of pure stock
cultures of :robacco ~o~~:i:c£ .Yirus var. vul~qris Ul strai.n, a
were prepared using molecularly filteredb Sterile Water for
Injection U.S.P.c as a vehicle.

The required vol.umes were

micropipettedd ihto sterile one ml glass
flasks.e

s~oppered volumetric

The micropipette tips had been ethylene oxidef

kObtained from T. Shalla, Ph.D., Dept. of Pl~nt Pathology,
University of California, Davis, CA.
bl42 mm Hi Flux U-F Cell equ:ipped with a Pellicon PTGC
membrane, 10,000 nominal molecular weight retention limit,
available from Millipore Corporation, Bedford, MA.
cAbbott Laboratories, North Chicago, IL.
dFinpipette, Code 11, available from Vangard International, Neptune, NJ.

e

Class A, Pyrex Brand, available from Dow Corning,
Midland, MI.
fPenngas, available from Pennsylvania Engineering Co.,
Philadelphia, PA.
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steri.ltzeda prior to their use.
in a laminar

a~r-flow

All dilutions were prepared

area using a Class 100 high-efficiency

particulate absolute filter.b
Preparat ion a nd Monitoring of Molecularly Filtered Sterile
Fat~I-

for Inj ec tion

Through o ut this investi ga tion molecularly filtered
ste ril e water for injection (W!'SWFI) was u sed.

This water

was Sterile Wate r for Injection U. S.P. (SWFI) whi c h had b een
subjected to molecular filtration to remove any particulate,
bacterial , fungal, or viral co nt amination.
Liter (L) volumes of SWFI were filtered throug h a
Pellicon mol ectil ar filter having a nominal molecular weight
r ete nt ion lim i t of 10,000.
142 mm Hi Flux U-F Cell.

Thi s filter was co nt ained in a
The solution was loaded into the
('

cell by use of a .standard i n travenous administration se t. ·
A l

r~

t o 20 pslg.
. d d r1v1ng
. .
f·orce was genera t e d b y d ry g ra d e

nitro g~ n e passe d through a 25 mm, 0.2 ~m inline Fluoropore

aAMSCO Cryotherm and Aerator, available from Amsco
Industrial Co., Erie, PA.
bGEN II , available from Plas-Labs , Lansi ng, MI .

c

Ve nos et-6 0, available fro m Abbott La boratories, North
Chicago, IL.
d

Pounds per square inch gau ge .

eAvailable from Union Carbide Corp., Linde Division,
New York, NY.
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filter.a

A Hi Flux U-F Cell agitator setting of two was

used during the filtration.

The filtrate was collected in

stoppered, sterilized flasksb and stored in a laminar flow
hood.
All filtration equipment including accessories was
cleaned, then ethylene oxide sterilized prior to use.

Through-

out the project any equipment not subjected to this type of
sterilization was either dry heat sterilizedc at 160 to 170° C
for at least three hours or autoclaved

d

at 15 psig. and

121° C for the correct penetration time for the load.

Chemi-

cal indicatorse,f were used to monitor the sterilization
procedures.
The entire filtration procedure was performed in a
laminar air-flow work area containing a Class 100 highefficiency particulate absolute filter.
Whenever MFSWFI was prepared, contamination control

aMillipore Corporation, Bedford, MA.
b

Fleakers, available from Dow Corning, Midland, MI.

c Thelco Dry Heat Oven, available from Precision Scientific Group, GCA Corp., Chicago, IL.
dModel No. 999 - C, available from Wilmot Castle Co.,
Rochester, NY.
eEthylene Oxide Indicator, available from Aseptic
Indicator Co., North Hollywood, CA.
f3M Autoclave Tape, available from Minnesota Mining
and Mfg. Co., St. Paul, MN.
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detection procedures were used.

The stored filtrate was

subjected to sterility testing for bacterial and fungal contamination.

The following procedures were used:

At least 10 ml of MFSWFI were aseptically transferred
to not less than 80 ml of sterile Fluid Thioglycollate
Mediaa (FTG) and to not less than 80 ml of sterile
Sabouraud Dextrose Brothb (SDB).

At the same time

blank controls, as well as contaminated controls were
prepared.

The blank controls detected contaminated

media or septic procedures.

The contaminated controls

were used to test the media's ability to support bacterial or fungal growth.

A contaminated bacterial

control was prepared by inoculating nat less than
50 ml of FTG with Ba~_:i,l..!_~s subtilj~· c

A .contaminated

fungal control was prepared using Can_dis!~ _i!:._l_!:li~'':E!..."::d
inoculated into not less than 10 ml of SDB.

The

bacterial contamination tests were incubatede at
30 to 32° C, whereas the fungal contamination tests
were incubatedf at 22 to 25° C.

The tests were checked

aDifco Laboratories, Detroit, MI.
bibid.
c Bakte Bennet Labs., Berkeley, CA.
dibid.
j

'

eThelco Incubator, available from Precision Scientific
Group, GCA Corp., Chicago, IL.
flbid.
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for growth daily for not less than 14 days.
The results of_all tests performed showed no bacterial or
fungal co ntamination of the MFSWFI or the blank contro ls.
Growth occurred in all contamination controls.
To determine the pr esence of inc idental viral contaminat ion of the MFSWFI by TMV or any o the r virus, the fol l.owi ng
procedure was used:
The residual volume of SWFI r emaining in the lii Flux
U-F Cell was remov e d by nitro ge n pressure via the
cannula attached to the cell.

Sterile s ur gical tub inga

attached to the cannul a enabled the collect i on of the
sampl e in a sterile 20 by 150 mm · Pyrex test tube.b

This

r es idual volume was r eferred t o as the retent ate volume.
Two to fo ur: dr ops of the f Jl tr a te, MFSWF I., were a l s o
collected in anot h e r steril e test tube.

The inline

Fluo r opore filte r u sed t o filter th e nitrogen was asep-·
tic a lly remove d in the l a min a r a ir- flow hood.

It was

tr a nsferr e d to another sterile tes t tub e co nt a inin g
0 .5 ml of MFSWFI.

The r etentate volume, f iltrate, and

inline filt e r co llect volume were the n prepar ed into
ne gativ EC stained specimens for tr a nsmiss i on electron
microscopy by the fo llowing procedure:
Two microl it e r s

(~1)

of each solution were deposited

aTygon tubing S 50-HL, available f rom Norton Plasti cs
and Synthetics Divis i o n, Akron, OH.
bAvailable from Dow Corning, Midland, MI.
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on 400 mesh copper grids . a
the grids had been

In a laminar flow hood

subst~ated with Formvarb and

stabilized with a layer of vacuum evaporatedc carbon.

The solutions were deposited on the grids

by the use of sterile micropipet t es.d

Two

~1 of a

0.5% wfv solution of uranyl acetate (UA) in MFSWFI
were then deposited to the grid.

This embedded

the sample specimen in the UA negative stain.

This

procedure has been described by Hasch e meyer and
Myers (74) as the "drop method."

Prior to the use

of the UA solution, it had been filtered through a
25 mm PTGC Pellicon fil tere . po.s sessing a no minal
molecular weight retention lim:i t of 10 ) 000 .

rrbe

grid pre paration was allowed to dry comp le tely in
the le:tminar air-flow envlronment .

It was t hen
f

examin e d jn the transmission e l e c t ron microscop e '

g

at 50 or 60 KVh and a magnlfication of at leas t 18,000.
aAvailable from Ted Pella Co., Tus tin, CA.
b0.2 pm Fluoropore filt e r e d 0.25% wfv Formvar in Ethylene
Dichloride.
cVari a n Vacuum Evaporator, VE 10, availabl e from Varian/
Vacuum Division, Palo Alto, CA.
dAvailable from Drummond Scientific Co., Broomall, PA .
eMillipore Corporation, Be dford, MA .
fRCA TEM EMU3-DX, available from Radio Corp . o f America,
Camden, NJ.
gSiem e ns Elmiskop TEM IA, available from Si e me ns o f
America, Inc., New York, NY .
hKilovolts.
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Throughout the project TMV was not detect e d in any of these
control specime_ns for MFSWFI.
A proce dural diagram of the preparation and monitoring
of MFSWFI is prese nted in Figure 1.
Parent eral Solutions
In this study defined volumes of Sodium Chloride Injection U.S.P. and 5 percent Dextrose Injection U.S.P. were the
parenteral solutions examined.

Ide ntical lots of the speci-

fied volumes of each solution were randomly chosen.

These

were then used throughout either the preliminary tests
involving small volume parenterals or the tests with large
volume infusions.
These two parenteral so lutions were chosen because
they or their varying combinati.ons comprise the most corrunon l y
administered intravenou s infusions.
Preliminary Tests with Small Volumes of Parenteral Solu!tons
The Test Method
A 10 ml aliquot volume was aseptically r emoved from a
50 ml volume of either Sodium Chloride Inj ection U.S.P.a
or 5 percent Dextrose Injection U.S.P.a

This volume was

transferred to a ster ile 16 mm by 125 rnm test tubeb for each

aMcGaw Laboratories, Irvine, CA.
bPyrex brand, available from Dow Corning, Midland, MI.

------------~~~--------------------------~-------------------------------.----1-------------------
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analysis.

This solution was inoculated with TMV by the use

of a micropipette with a sterile tip.

The virus was obtained

from the serial dilutions of TMV already described.
After inoculation, the solution was gently agitated
and then filtered using a Pellicon PT series molecular filt er un1"t·. a

ll cm

2

The filter on this unit had a surface area of

b and a nominal molecular weight retention limit of

10,000. The solution was filtered by the use of a vacuum
c
pump attached to a collection reservoir. The retentate
volume remaining in the test tube after filtration was
approximately 0.2 ml.

The test tube and filter were then

washed with a five ml portion of MFSWti, again conceatrated,
then rewashed wi t.h another five ml . volume of
volume was again reconcentrated to 0.2 ml.

~lFSWFI.

This

After each fil-

tration procedure, the filter was tested to ensure filter
integrity as described by the manufacturer (120).
Two

~l

volumes of this retentate volume were deposited

using a sterile micropipette on Formvarjcarbon substrated

400 mesh copper grids.

A two lll volume of 0.5% wfv uranyl

acetate solution in MFSWFI was then placed on the specimen
grid.

For each test specimen four grid preparations were

aimmersible Molecular Separator, available from MillJ.pore Corporation, Bedford, MA.
b
j

'

Square centimeters.

cAvailable from Millipore Corporation, Bedford, MA.
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made.

Two of the samples were allowed to dry completely on

the grids and two were blotted with sterile filter po.per
after five minutes from the time of application of the stain.
All procedures described above were conducted using aseptic
techniques in a laminar air-flow environment.
To single blind the experiments, the specimens were
exami.ned for the presence or absence of TMV by an electron
microscopy technician.

Prior to this study, the technicians

were instructed in the technique of negative staining and
transmission electron microscopic observation of TMV.
Cleaning,

~anitizing,

and Sterilizo.tion of the

Molecular Filters
At the completion of each test using rr.olecular fil h·a-tion, the filter was cleaned with a one

% wjv

chlorite solution for at least three hours.

sodium hypoThis solution

was discarded after passing through the filter.

At least

50 ml of MFSWFI were used to rinse the filter and the filter
unit's inner matrix.

The filter was then flushed with and

placed in a two

% wjv

than 14 hours.

This formaldehyde solution was passed through

formaldehyde solution for not less

the filter and discarded.

At least 80 ml of MFSWFI were

filtered through the membrane before its use in the next
test.
j

i

After every fifth test, a new molecular filter was

selected and ethylene oxide sterilized prior to use.
Figure 2 diagramatically describes the test method as
well as the cleaning, sanitizing, and sterilization procedures

I.

Sterilization
of ll cm2
/)
Molecular
Filter
~

Load Test Tube
with Parenteral,
Inoculate with TMV,
and Filter
Corcentrating to
Retentate Volume
of 0.2 ml

Flush
) with 2 - 5 ml
Volumes of
MFSWFI
Concentrating to
Retentate Volume
of 0.2 ml for
Each Flush

~

Retain
Retenta te
Volume

7Examine
Using
N.S.
and
EM

Fi~h ~heck

Clean
l % wjv Sodium
Hypochlorite
Solution

Filter
Integrity

. J

R1nse and Flush
Filter with Not Less
Than 50 ml of MFSWFI

~

Sanitize Filter
with 2 % wjv Formaldehyde Solution

J

Rinse and Flush
Filte~ with Not Less
than 80 ml of MFSWFI

Figure 2.
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of Parenteral Solutions.
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used with small volumes of parenteral solutions.
Detection of TMV at Varying Viral Contamination Levels
Initially, it was necessary to identify approximate
viral contamination levels which the test method could detect.

The test method as described above was used for all

of these determinations.

The amount of the viral inoculum

and tho parenteral used in each test are shown in Table I.
The tests were first conducted using Sodium Chloride
Injection U.S. P.

The tests were then repeated using 5 per-

cent Dextrose Injection U.S.P. at the lower contamination
levels.

These tests were concluded when a level of contami--

nation in Sodium Chloride Injection U.S.P. was reached at
which TMV could not be detected.

The results are reported

in Table I.
Based on the results of these tests, the 100 I.U. and
l I.U. TMV contamination levels were chosen to evaluate the
efficacy and efficiency of the test method.
trols were established.

Suitable con-

Replications of each control and

test treatment were performed to provide statistical validity.
Efficacy Determination at a Contamination Level of

100 I. U. of TMV per MilliUter of Sol11tion
To determine the efficacy of the test method with small
volumes of parenteral solutions at a contamination level of

100 I.U. of TMV per ml of solution, the following tests
were performed:
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TABLE I
PRELIMINARY TEST RESULTS
Detection of Tobacco Mosaic Virus.in
Small VolumesofParenterals at
Varying Viral Contamination Levels

Viral Contamination Level

Results Observed Using Sodium

in Virus Particles (V,P.)

Chloride Injection U.S.P.
and 5 percent Dextrose

and Infectious Units (~)
per Milliliter of Parenteral
V.P.

I. u.

1010
9
10
8
10
7
10
6
10
5
10

10,000

NS

(D5W)

D5W

1,000
100

+

10

+

1

less than 1

aTMV observed.
bTMV not observed.
j

Injection U.S.P.

+

b

(~lS)
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Ten ml of Sodium Chloride Injection U.S.P. were
aseptica~ly

removed from a 50 ml volume of this solution

and transferred to a sterile 16 mm by 125 mm test tube.
This sol uti on was inocula ted with 100 I. U. of TMV as
performed in the initial tests.

The solution was

gently agitated to disperse the virus.

Two )11 of this

mixture were then deposited on a Formvarjcarbon substrated 400 n•esh copper grid and negatively stained
by the prior method.
followed.

Electron microscopic examination

This procedure was repeated for a total of

three replications with Sodium Chloride Injection U.S.P.
and followed by three replications with 5 percent
Dextrose Injection U.S.P.

Thus, these contaminated

solutions were examined for detectability of TMV without
use of the test methodology.

The results are found in

Table II.
After these control tests, the same inoculation
procedure with 100 I.U. of TMV was performed on the
same volumes of the parenterals.

These were then sub-

jected to the filtration methodology described above
in the initial tests.

Three replications were conducted

with Sodium Chloride Injection U.S.P. and then repeated
with 5 percent Dextrose Injection U.S.P. Single blind
electron microscopic examination was performed after
the use of the test methodology.
also presented in Table II.

These results are
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TABLE II
PRELIMINARY TEST RESULTS

Determination of the Efficacy of the Test Method
with ,?EJall Volumes of Parenteral Solutions
at a Contamination Level of 100 Infectious
Units of Tobacco Mosaic Virus per
-~-Mill-iliter of Solution-

TMV Not
Observed

TMV
Observed

Total

Examined Without
Use of the Test
Methodology

6

0

6

Examined After
Use of the Test
Methodology

0

6

6

Total

6

6

12

Calculated P = 0.00108
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Th e dat a present e d in Tabl e II and all subseq uent
tables thro u g hout thi s re sear c h we re analyzed by the
Fishe r e xact probability t est

(117).

Efficacy Dete rminatio n at a Contamination Leve l of· 1 I . U.
~-~

TMV p e r Millilit e r of Solution

Once efficacy d e termination o f th e t es t method had b een
complete d at a contamination l eve l of 100 I . U. of · TMV p e r ml
of pare nt e ral, th e e ntire proce dur e describe d abo ve was repea ted .

Thi s proce dure was rep eated with a TMV con tamin ation

level o f 1 I.U . per ml of so lution.
and th e same parenteral sol utions,

Us in g the same vo lumes
si ~

replications were

p e rf ormed at this contamination l eve l with out th e us e of the
test me thodology .

These were fo llowed b y six

fi s in g th e t est procedu re .
duct ed on a ll specime ns.

r ~plications

Sin g l e blind exami n ation was conThe r esults are s hown in Table I II

for contamin at ion l e v e l s of 1 I . U. per ml of so lution .
Efficiency Determin ation at a Con tamination Level of
100 I.U . of TMV

p~r

Milliliter of Solution

The eff i cien cy of the t es t method with small volumes
of the pare nt e r a l s at a contamination level of 100 I . U. of
TMV p er ml of so lutio n was det e rmine d.

Three r ep l icates of

10 ml volumes of Sodium Chloride Injection U. S . P . a n d thr ee
r ep l i cat es of 10 ml volume s o f 5 p e r cent Dextrose Inj e ction
U. S.P. were u sed in each t es t group .
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TABLE III
PRELBliNARY TEST RESULTS

Detcrmina t ion of the Effi.Cf!S.Y.: of the Test Method
with Small Volumes of Parenteral Solutions at
a Contarnfnation Level of 1 Infectious Unit
of Tobacco Mosaic Virus per Miliiliter
----of-Solution
TMV Not
Observed
Examined Without
Use of the Test
Methodology
Examined After
Use of the Test
Methodology

Total

TMV
Observed

Total

0

6

6

____________ , _ _ _ - - - - l
1

-;

6

----------- ---------------'7

Calculated P = 0.00866

-'
'

5

5

12
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In the first group of tests, the control group, the
parenterals were not contaminated with TMV.

The second group

of tests, the treatment group, was contaminated with 100 I.U.
of TMV per ml for each test solution.

Thus, one group was

not contaminated and the other group was contaminated with
the virus.
Each parenteral test specimen in a group was subjected
to the filtration test method described in the efficacy determinations.

The cleaning, sanitizing, sterilizing, sampling,

staining, and examining procedures accompanying the filtration
were used and remained unchanged.

The results of electron

microscopic examination of the specimens for the presence or
absence of 'l'MV are found jn Table IV.

A representative elec-

tron micrograph is provided in Figure 3.
Ef_fieiency De_terminaUon at a Contamination..]k_Y-<':.!_of
1 I.U. of TMV per Milliliter of Solution
The efficiency of the test method was next determined
using a contamination level of 1 I. U. of TMV per ml of the
parenteral solution.

The same parenterals, volumes, and

replications were used here.

The uncontaminated control

and the contaminated treatment groups' observations are summarized in Table V.

Figure 4 illustrates the typical find-

ings upon electron microscopic examination.
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TABLE IV
PRELIMINARY TEST RESULTS

Determination of the Efficiency of the Test Method
with Small Volumes of Parenteral Solutions at
a Contamination Level of 100 Infectious Units
of Tobacco Mosaic Virus per Milliliter
------- ----or-solution
TMV Not
Observed
Uncontaminated
Parenteral Exawined
After Use of the
Test Methodology

6

Contaminated
Parenteral Examined
After Use of the
Test Methodology

Total

TMV
Obse!'ved

-,

0

6

0

6

6

6

6

12

Calculated P = 0.00108

_j'

'

Total
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Fig u re 3.

El ec t ron Mi crograp h o f Tobacco Mosaic Vi ru s
De t ec t e d at a Con tamin at i o n Leve l o f - - 100 In fec t ious Un its p er Mil lilite r o f
Sma ll Volume Pare n te r a l So lut i o n
(Magn ificat io n 98 ,000x )
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TABLE V
PRELIMINARY TEST RESULTS

Determinat ion of the EtficiencY._ of the Test Met hod
with Sumll Volumes of Parenteral Solutions at
a C;on-tarr1ina.tio n Level of 1 Infectiou s Unit
of Tobacco Mosaic Virus per Milliliter
--of- So 1 ut ion
TMV Not
Observed
Uncont ami nat ed
Parenteral Examined
After Use of the
Test Me thodology

TMV
Observed

Total

r-----------~-----------

6

0

6

t--- - - - +----··-·- -

Contaminated
Parent eral Examined
After Us e of the
Tes t Methodology

l

5

6

Total

7

5

12

Calculated P = 0.00866
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Figure 4.

El ec tron Micrograph of Tob acco Mosaic Virus
De tect e d at a ContaminatianLe v el - of--1-- In fectiou s Unit per Milliliter of Small Vol ume
Parente r a l Solution.
(Mag uif ieation 98,000x)
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Tes ts with La rge Volumes of Pare nt e ral Solutio n s
The Tes t Method
The test method for the d e tection of viral co ntaminati o n
of small volume parenterals u s ed a molecular f iltra t ion mem.

2

brane with an a r e a of ll em .

For bulk p a rent era ls, a l arger

filtration me mbrane wa s neede d to r e duce fil t r atio n time.
The Hi Flu x U-F Ce ll, e quippe d

with

a 1'12 mm molec ul a r f il·-

ter with a no minal mol ecul a r we i ght r e t e nti o n limi t o f 10,000 ,
was chosen to provide large volume filtra t i on .
me mbrane provided 158 . 37 cm

2

of filtrat ion ar e a.

Th e 14 2 mm
Thi s c e ll,

filter, and the acc ess o r ies acco mpan y in g the ir u se , h a v e b een
d escribe d in

~h e

p r eparat i on o f MFSWFI .

A o n e lit er vo lu me of e ith e r

So dium Ch l ori d g I nj e c t ion

c· . rr ' .-a wa.s asep t 1.'
US
. .... P. a or :'>pe r cent Dextrose I DJ. ec t '1-011 up . •.

cally tr ansfe rr e d t o the ce ll by a
. t r a t 1o
. n se.t . b
m1.n1s

stand ~ r d

i n trave nous ad-

The c e ll i nl e t port a l was sea l e d a nd a

15 to 20 p s i g. driv i n g fo r ce was a ppli e d b y dry g r a d e nitr oc .
gen' passe d throu gh a 2 5 mm, 0 . 2 ~m inlin e F luo r opo r e f ilt er .

d

On ce t h e ce ll v e n t v a lve was c losed, f ilt ratio n began .

Du r in g fi l t r a tio n a ce ll ag it a tor se t ti n g of t wo was u sed .

a Abbo tt La b orat ories , Nort h Chi cago , I L .
b

Ve nose t -60, avai l a bl e fro m Abbo tt La bo r a t o ri es , Nort h
Chi cago , IL .
c Ava i labl e fro m Uni o n Carbid e Co r p . , Li n d e Di v i s i on ,
Ne w Yo r k, NY .
dMill ipore Corporat i o n, Be dfo rd, MA .
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The agitator prevented concentration polarization at the
membrane surface, which would reduce the flow rate and alter
the retention characteristics (108).

The sol ution was con-

centrated to a volume less than three ml.
After this initial filtration procedure, the c e ll was
aseptically filled with approximately 250 ml of MFSWFI .

This

volume was then filtered and concentrated to less than three ml.
Again 250 ml of MFSWFI were aseptically added to the cell.
This final rinse was filtered and concentrated to less than
thre~

1nl.

Just prior to the final concentration, about 0 . 2 ml

of the filtrate was collected in a sterile test tube and
retained for analysis.
The retentate ~olume in the cell was aseptically removed
through the cell cannula by nitro ge n pressure .·

Tl1e retentate

volume was forced through the cell c&nnula, sterile surgical
tubing,

a

.

and another cannula into a sterile 20 by 150 mm

Pyrex t est tube.

b

Once this retentate volume was collected, th e volume was
furth er concentrated to approximately 0.2 ml.

An ll em

2

Pellicon PT se rie s molecular filter unit with a nominal molecular weight retention limit of 10 ,000 was u se d for this concentration procedure.
aTygon t~bing S 50-HL, available from Norton Plastics
and Synthetics Division, Akron, OH.
bAvailable from Dow Corning, Midland, MI .
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This r ete ntat e volume and the collected filtrat e wer e
subjected to the same n ega tive staining procedure and single
blind

electron

microscopic examination as described in the

preliminary tests.

The same volumes of the sampl e and stain

as well as the same number of grid preparat.ions per specimen
were used.
All of the above procedures for th e test me thod wer e
conducted in a lamina r air-flow hood.
Cleanin~1

S a nitizing, and Sterilization of the Cell and

th e Molecular Filter
After each test the 11 em

2

molecular filter unit was

cleaned with sodium hypochlorit e solution and sanitized with
formald e hyde solution.

Tlle procedure h as been descrtbed in

the preliminary tests.

Following eve r y fourth test, a n ew

filt er unit wa$ selected.

Prior t o its use the new unit was

ethylene oxide sterilized.
The Hi Flux U-F Cell and the 142 mm molecular fj.l ter
we r e cleaned and sanitized in situ by the foll owing procedure :
1.

A 500 ml volume of one % wfv sodium hypochlorit e was

placed in the cell by use of a standard intravenous administration set.

This cleaning solution was agitated in the

cell and a small volume was allowed to pass through t h e
filter.

The remainder of the solution was retained in the

cell for at least thr ee hour s.

After this interval , the

solution was filtered and disc ar ded.
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The ce ll was then rinsed with two, 250 ml volumes

2.

of MFSWFI .

Eac h volume wa s ag itat e d throughout t h e cell,

then flushed thro u g h the filt e r .
3.

Five- hundr e d ml of two

were pl aced in the cell.

% wjv

formald e h yde solution

This was followed by co n t r olled

agitation to e nsu r e a uniform covering of the ce ll s u rfaces .
A s ma ll volume of thi s solution was filtered thro ugh the membra n e .

Th e n th e sol u t i o n was r etain e d in th e cell for not

l ess than 14 h o urs .

At the e nd of this san itizing procedure,

th e ce ll was flu s h ed a nd the so lutio n was d isca rded .
4.

A 2 50 ml volume o f MFSWFI was plac ed in th e ce ll .

Th e cell was thoro u ghly rinsed with t h e MFSWFI.
was then fi lt ered through the membrane.

The MFSWFI

This r ins in g pro-

ced ur e was performed a t o t a l of four t imes to .e f fe ctive l y
r emove tr aces of forma ldehy d e.
rin se was

coll ~c ted

Th e MFSWF I u serl f or the fourth

a nd ana ly ze d for its form a ldehy de con-

t e nt . . Th e rete n tate volume was analyzed for r esidua l TMV by
th e t est method d esc ribed previously .

TMV could not be

d etect e d in this rins e retentate volume throu g hout th e tests.
The fo rma ld ehy d e co nt e nt i n the rin se was a n a l yzed by a procedure simi l a r to th e method described in t h e U. S . P . (lJ.B)
and the method of Bricke r an d J o hn so n (119).

Th e followin g

pro cedur e was us e d:
Five mg of chromotropic aci d were dissolve d in t e n ml
of a mi x tur e of nin e ml of Sulfuric Acid U.S. P . a n d
four ml of disti ll e d wat e r .

Fi ve ml of thi s sol u tion were
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added to 0.2 ml of the formaldehyde rinse.

The mixture

was then heated for 10 minutes at 60°C on a water bath.
A very faint violet color resulted.

The amount of

formaldehyde was determined spectrophotometricallya
at a wavelength to 570 nm by comparison with a reagent
blank.

A series of formaldehyde reference standards

were prepared and analyzed.
structed.

A Beer's Law plot was con-

The average amount of formaldehyde detected

in the fourth rinse was less than 3.5 micrograms

(~g)

per ml.
After the completion of every fourth test using the Hi
Flux U-F Cell and its molecular filter, the cell was disassembled, eleaned with mild detergent, and thoroughly rL1sed
with copious volwnes of distilled water.

The cell and its

components were then dried in a laminar air-· flow hood.

After

drying, a new 142 mm molecular filter and a new inline Fluoropore filter were installed.

The cell and all accessories

were then ethylene oxide sterilized.
At this disassembly time, the Fluoropore inline filter
was aseptically removed in the laminar air--flow hood.

The

filter was placed in a sterile test tube containing 0.5 ml
of MFSWFI.

The tube and its contents were agitated.

Nega-

tively stained specimens were then prepared for electron
-

~

•Perkin-Elmer Model 202 Spectrophotometer, available
from Perkin-Elmer, Norwalk, CT.

i
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microscopic examination.

This procedure has been described

in the preparation and monitoring techniques for MFSWFI.
Throughout the experimentation TMV was not observed in these
Fluoropore filter washings.

This procedure was used to

detect incidental contamination from the nitrogen sourc~.

A procedural diagram of the test method including the
cleaning, sanitizing, and sterilization methods is shown in
Figure 5 for large volume parenterals.
Efficacy Determination at a Contamination Level of
lOO__!..:_Q_,__of TMV per Milliliter of Solution
The efficacy determination tests performed with large
volume parenterals were similar to those executed in the preliminary tests with small volume solutions.

The control tests,

which were examined without use of the test methodology, were
conducted exactly as described in the preliminary tests using
100 I.U. of TMV in 10 ml aliquot volumes of the parenterals.
However, the procedure was repeated for a total of four rep-·
lications with Sodium Chloride Injection U.S.P. and followed
by four replications with 5 percent Dextrose Injection U.S.P.
The results of the control tests inoculated with virus but
examined without use of the test methodology are described in
Table VI.
Following these control tests, 1000 ml volumes of the
parenterals were placed in the Hi Flux U-F Cell and inoculated with 100 I.U. of TMV per ml.

i

Inoculation was performed

by use of a micropipette with a sterile tip.

The contaminated

_ ............. ,•.•, ......1 •..•••,.

Sterilization
Load Cell
of Hi Flux ~with Parenteral, )
U-F Cell,
Inoculate with
Molecular
/f THV, and Filter
Concentrating
to R e t e n t a y e
Volume of Less
Than 3 ml
Collect 0. 2 ml
of Filtrate

Jr

Integrity Test
Filter for THV
Breakthrough
Using N.S. and

Flush with
Remove
Retain
) Examine
2 - 250 ml Volumes
Retentate
Retentate
Using
of MFSHFI ConcenVolume
Volume
N.S.
trating to Retentate
from C e l /
and
Volume of Less Thavand Retain
EM
3 ml for Each Flush
~
\V
Clean Hi Flux U-F Cell
Concentrate to
Sterilization
and Molecular Filter
Retentate Volume
of 11 cm2
in situ with 500 ml
of 0. 2 ml with
~
Molecular
of 1 % w/v Sodium
11 cm2 Molecular
~
Filter
Hypochlo~te Solution
Filt~

I

Rinse and Flush Cell
and Filter with 2 250 ml Volumes of
MFSHFI j

Hypochlorite
Solution

Sanitize Cell and
Filtec with 500 ml of
2 % w/v Formaldehyde
Solution~

Rinse and Flush Filter
with Not Less Than
50 ml of MFSHFI
~

Rinse and Flush
Cell and Filter with
4 - 250 ml Volumes of

Sanitize Filter with
2 % w/v Formaldehyde
Solution

~

D

~

HFS'wFI

Analyze Fou
MFSHFI Rinse for
Formaldehyde
Traces

~

rility TCst
R entate VoJ.ume from
Foucth MFS'IFI Rinse
for TffV and Otl1er Contaminants Using N.S.

Clean Filter with
1 % w/v Sodium

~

-t

Rinse and Flush Filter
with Not Less Than
80 ml of HFSWFJ.

_j

and EM
Figure 5.

Procedural Diagram of the Test Method with

La~ge

Volumes of Parenteral Solutions.

"""
-..:!
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TABLE VI
TEST RESULTS

Determination of the Efficacy 6f the Test Method
with La!·ge Volumes o.f Parenteral Solutions at
a Contamination Level of 100 Infectious Units
of Tobacco Mosaic Virus per Milliliter
of Solution
TMV Not
Observed
Examined Without
Use of the
Test Methodology

TMV
Observed

8

0

Total

8

1------t----·----Examined After
Use of the
Test Methodology

0

8

8

Total

8

8

16

Calculated P = 0.000078

.,
'
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solution was pro cessed by the test method .

Four replications

with Sodium Chloride Inj ect ion U.S.P. and four r eplications
with 5 p e rcent Dextrose Inj ect ion U.S.P. were conducted .
These res ults are summarized in Table VI.

The 0.2 ml volume

of filtrate co ll ected at the end of each procedure did riot
demo nstrate any TMV breakthrough from the molecular fi l ter.
Effj_ ~3CY

_Det e rmination a t a Con t amtna t ton Level of

1 I .U . of TMV_per Milliliter of Solution
Aft e r efficacy de termination of the test method had been
completed a t a co ntamination level of 100 I. U. of 'l'MV per ml of
bulk parenteral, the entir e pro cedure e nume r ated above was again
r epeated.

For .these tests a TMV contamination level of 1 I. U.

per ml of solution was us e d.

The r esults of the controls,

examined without use of the tes t met hodo l ogy, ·a nd th e test
trea trnent g r oup, examin e d afte r use of
presente d i n Tabl e VII.

th<~

t est method, a r e

Agai n, th e 0. 2 ml volumes of filtrate

collected at the e nd of each procedur e s ho wed no TMV breakthrough .
Efficiency Determination at a Contamination Le ve l of
100 I.U. of TMV per Milliliter of

Solutio~

The efficiency o f the test methodolo gy with large vol umes
. of the parenteral soluticins was determined .

The co ntaminatio n

l e vel of 100 I.U. of TMV per ml of bulk infusio n was first
examined .

Lit e r volumes of Sodium Chloride Injection U. S . P .

and 5 percent Dextrose Injection U.S.P. wer e used in t he
tests.

Fo ur replications of the test method fo r each of t he

two sol uti ons were performed i n a test group.
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TABLE VII
TEST RESULTS

Determination of the Efficacy of the Test Method
with Large Volumes oO'arenteral Solutions at
a Contamination Level of 1 Infectious Unit
of 'I'obacco Mosaic Virus per MillUiter
of Solution
TMV Not
Observed

8

8

Examined After
Use of the
Test Methodology

3

8

5

ll

Calculated P

•

Total

Examined Without
Use of the
Test ~Iethodology

Total·

,

TMV
Observed

=

0,017093

16
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The control tes t group of pare nterals was not contaminat e d with TMV:

The test treatme nt group was contaminat e d

with 100 I . U. of TMV per ml in each bulk pare nteral.

Th e

inoculation procedure was the same as that describ e d fn th e
efficacy tes t s .

Each infusion, wh e ther contaminated or un-

contaminated, was subjected to th e t e st metho d de scribed
prevj.ous ly.

The re s ults are r e port e d in Table VI II and

illustrat e d by a repr esentative electron micro g raph in Figure 6.

No TMV breakthrough was found in the filtr ate volumes

collec t e d.
Effici e ncy

~etermin a tion

a t a Contaminatio n Level o f

1--l.:.!:!...:__s>f TMV p e r Millilit er of Solution
The efficiency de t ermi nat i o n met hod prese nt e d above was
r e peate d at a contamination l evel of 1 I.U . of TMV p e r ml
of the parenteral.

The same par e nterals, volumes, and replf-

cations we r e used for th ese tests .

The un co nt a min ate d a nd

contaminat e d gr o up s ' r es ult s are r ecorde d in Ta bl e I X.

F'ig·-

ure 7 d emons trates th e typical finding of e l ec tro n microscopic exami natfon .

TMV breakthrou gh was not observed fn

the collected filtrate .
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TABLE VIII
TEST RESULTS

Determination of the Effictencx of the Test Method
with Large Volumes of Parenteral Solutions at
a Contamination Level of 100 Infectious Units
of Tobacco Mosaic Virus per Milliliter
--ofSolution

Uncontaminated
Parenteral Examined
After Use of the
Test Methodology

TMV Not
Observed

TMV
Observed

Total

8

0

8

--

r·

Contaminated
Parenteral Examined
After Use of the
Test Methodology

0

8

8

Total

8

8

16

Calculated P

-~
_\

l

= 0.000078
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Figure 6.

Electron Micrograph of Toba cco Mosaic Virus
De tected at a Contamination Level of lOb---Infectious Units per Milliliter of Large
Volume Parenteral Solution (Mag11i ficatio n 98,000x)
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TABLE IX
TEST RESULTS

Det e rmination of th e Effi c iency of the Test Me thod
with La rge Volumes of Pare nt e r a l Sol uU.ons at
a Contamination Le vel of l Inf ect ~o~s Unit
of Tobacco Mosaic Vi~us pe r Millilite r
-----

of Solution

TMV Not
Obse rve d

TMV
Ob serve d

Total

0

8

Uncontamina t ed Pare nteral Examin e d Aft e r Use of the
Test 111e th o dology

~------------- ~----------~

Contaminat e d
Parenteral Examine d
Aft e r Use of the
'rest Methodology

'--- - --

Total

5

3

8

- L--- --·--~-

ll

Calculate d P = 0.017093

5

16
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Figure 7.

Electron Micrograph of Tobacco Mosaic Virus
De tected at a Cont a min a tion ·L evelof- 1.- In fec tiou s
Unit per Millilit er of Larg e Volume Parenteral
Solution (Magnifi cation 71,000x )

DISCUSSION
In this study both efficacy and efficiency were desired
for th e proposed test method of detecting viral contamination
in parenteral solutions.

The 100 I.U. a nd l

I.U. TMV contami-

nation l evels identified in the preliminary tests enab l ed
effective evaluation of the method.

Using the preliminary

test method, TMV was not detected at a viral contaminatio n
level less than 1 I.U. per ml of small volume parenteral
solution.

This was s hown in the r esult s- pres e nted in Table I.

For the prelimtnary tests with small volume parenteral
so lutions and th e s ubsequent tests with l arge volume parenteral sol utions, the controls u sed in th e eff icacy dete rmi n a tion s of t h e

~e s t

n~t hod

were contaminated with ei th e r

100 I.U. or 1 I.U. of TMV per ml of parenteral solutio n.
These controls wer e examined for th e presence of TMV without
the use of the test method.

As reported in Tabl es II, III,

VI, and VII, TMV could not b e d e tected.

Wh e n specimens using

Sodium Chloride Injection U.S . P . were examin ed in th e electron
microscope , a dens e g ranular precipitate was observed.
precipitate hindered viral detection.

This

Upon e xamination of

spec ime n s using 5 percent Dextrose Inj ection U.S.P., s imil ar
result s were obtaine d.

The entire grid su r face of the

sample was electron d e nse .

This opacity of the sample prob a bly
56
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resulted from caramelization of the dextrose in the electron
beam.

When the test method was used for the efficacy test

treatment groups, viral detection was possible.

The rinsing

procedures and subsequent reconcentrations used in the test
method reduced the concentration of the chemicals interfering
with electron microscopic examination.
When using small volume parenteral solutions, the preliminary efficacy test results presented in Tables II and III
demonstrated significant statistical difference between the
control and the treatment groups.
100 I.U. contamination level
contamination level

(~

c

(~

This was noted at both the

= 0.00108) and the 1 I.U.

0.00866).

In Tables VI and VII, the

efficacy tests' results using large volume parenteral solutions showed significant difference between the contrpl and
the test treatment groups.
levels of 100 I.U.

(~ =

This occurred at the contamination

0.000078) and l

I.U.

(~ =

0.017093).

Thus, the efficacy of the test method for both small and
large volume parenteral solutions was established.
The efficiency of the test method at contamination levels
of 100 l.U. and 1 I.U. of TMV in small and large volume parenteral solutions was shown.
marize this evidence.

Tables IV, V, VIII,·and IX sum-

In the preliminary test and test con-

trol groups, incidental TMV contamination was not detected
using the test methodology.

Whereas in these same treatment

groups, contamin~ted with 100 or 1 I.U. of TMV per ml of
solution, TMV contamination was demonstrated by use of the
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test methodology.

For the preliminary tests with small

volume parenteral so lutio n s, statistically significant difference was observed between the control and treatment groups
for the 100 I.U. level
(P

=

0.00866).

<R =

0.00108) and the 1 I.U. level

The tests using large volume parenteral solu-

tions showed significant difference between the control and
test groups.

Efficiency of the test methodology for a TMV

contamination level of 100 I.U.

<R =

0.017093)

~as

demonstrated.

(~:

0.000018) and 1 I.U.

The electron micrographs

illustrated j_n Figures 3, 4, 6 , and 7 describe the relative
proportion of TMV occurrence as detected at 100 I.U. compared
with the 1 I.U. level.

Figures 3 and 6 show th e characteris-

tic clusters of many viruse s usually observed at the 100 I.U.
contaminatio n level .

At a contamination level of 1 I.U. of

TMV per ml of solution, singly occurring TP!V were u s u a J.l y
d e t ected .

These results are typifi e d in Figures 4 and 7.

SUM~tARY

1.

A survey of the lit e ratur e on parent e ra l contami-

nants, methods of parenteral contaminant detection, viral
c o ntamin ation of parent e rals, and methods of viral conce ntration was presented.

In this literat ure revi ew, no r efer-

e n ce was found describing viral contamination of pare nt e rals
or a method for dete cti n g viral contaminants in pare nt e ral
solutions.
2.

A method wa s de ve lop e d for dete!mining the presence

6f viruses in small volume as well as bulk parenteral s.

Th e

following methods and procedures were used to attain this
obj e cti ve:
a.

d~fin e d

volumes of Sodium Chloride Injectjon

U.S.P. and 5 percent Dext rose Injection U.S.P.
we r e inoculated with 100 I . U. or 1 I.U. of
Tobacc~

b.

Mosaic Virus ;

the cont e nts of th e parenterals were conce n trated to a retentate volume using mol ecul ar
filtration;

c.

the ret e nt ate volume was examined for vir a l
content using tran smission electron micros co py
with n egat ive staining techniques;

d.

the t es t method was evaluated for it s efficacy
and efficiency through ana lysi s of th e d ata
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by the Fisher exac t pro babil i ty t est.
3.

The r es ults showed that th e defined method of viral

d etec tion i s efficacio us and efficient at th e tested TMV
contami n a tion. levels for both s mall and lar ge volume pa r en t eral

soluti.ons.

CONCLUSIONS
A research met hod was d eve lop e d for d ete rminin g the ·
prese nce of virus e s in small volume as well as bulk parenteral
solutions.

Th e results of this experimentation s howe d that

the d ef ined method of viral detection is efficacious and effici ent at the test e d TMV contamination levels .

This test

me thod could probably be utiliz e d for the d e t ectio n of other
virai contaminants of parenteral solutions.

Furthermore, th e

ret e ntate volume, collected after the _concentration procedure
in the test methodology, may b e readily adapted to ani mal,
egg, or cell-culture inoculation for viral inf e ctivity analy-

sis .
The te s t method may b e classified as a destructiv e
met hod of co ntamin ant det ect ion in parentera ls since the content s of the parenteral must be removed from the cont aj_ ner
for exam in atio n .

Th e me thod does r e quir e careful attention

to the protoco l and can b e tedious .

Th ese di sadvant ages are

inh e r e nt.
This t es t me tho d is a dir ect met hod of viral contaminant
det ectio n and is a relativ e ly rapid process after the initial
materj.a l and equipment pre paration.

The information acquir ed

may be the most significant advantage t o be realized hy us e
of the t est me thodolo gy.
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The test methodology might find u se at · various levels in
the parent e ral ·so lution d e livery s ystem.

Pare nt era l manu-

factu rers could use this method to evaluate their products
for th e absenc e of virus at defin ed viral limits .

Analysis

of parent eral infusions for viral content might find use in
hospit als for the evaluat ion of "in use" standards or monitoring of admixture techniques.
The expe nse of producing· and administerj_ng a ste ril e ,
nonpyro ge nic, and viral-free infu sio n could be justified for
immunological ly incompetent pati e nt s.

Similarly, the expense

incurred in developing a viral r e t en tive inline final filter
could be justified.
Future studies u si n g this met hod or other more effective
~nd

effj.clent met hods s hould be und e rtaken to ·pursue the

assurance of viral--free parenteral sol uti o n s for improved
h ealth care .
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